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Abstract
Background: The relative survival field has seen a lot of development in the last decade, resulting in many different
and even opposing suggestions on how to approach the analysis.
Methods: We carefully define and explain the differences between the various measures of survival (overall survival,
crude mortality, net survival and relative survival ratio) and study their differences using colon and prostate cancer data
extracted from the national population-based cancer registry of Slovenia as well as simulated data.
Results: The colon and prostate cancer data demonstrate clearly that when analysing population-based data, it is
useful to split the overall mortality in crude probabilities of dying from cancer and from other causes. Complemented
by net survival, it provides a complete picture of cancer survival in a given population. But when comparisons of
different populations as defined for example by place or time are of interest, our simulated data demonstrate that net
survival is the only measure to be used.
Conclusions: The choice of the method should be done in two steps: first, one should determine the measure of
interest and second, one should choose among the methods that estimate that measure consistently.
Keywords: Relative survival, net survival, Cancer registries, Population-based studies
Background
For decades, oncologists have shown a great interest in
a regular population-based evaluation of their efforts to
improve cancer outcome. Clinical trials do not bring
any information of the performance of the overall
“management” of cancer patients in the general popula-
tion. Because cancer patients can die from causes other
than the studied cancer, Ederer et al. [1] developed an
approach to measure “the survival rate so far as the dis-
ease under study is concerned” (later called the Ederer
I method). Later, Hakulinen proposed a corrected ver-
sion of Ederer I (Hakulinen method) that explicitly
aimed to account for competing causes of death by
adjusting for the population survival rate obtained from
the life tables, i.e. to estimate net survival as a measure
that would be comparable across groups with different
population mortality [2]. Both methods have been used
until recently by most population-based cancer regis-
tries (see e.g. SEER and EUROCARE 1–4). In the same
time, another method, often called Ederer II, has also
been applied (e.g. EUROCARE 5). Ederer II however
reproduces an oversimplification commonly made in
conventional survival analysis in a competing risks situ-
ation where the deaths of the causes, which are not of
primary interest, are simply censored. This method,
often referred to as cause-specific survival, is biased
when censoring is informative [3], i.e. when the patients
with a high hazard of one cause also have a high hazard
of the other cause, which is a common situation.
Recently, a specific effort was made to understand
the properties of these three relative survival methods,
and it has been proven that none of these methods con-
sistently estimates net survival [4]. At the same time, a
proposal for a consistent estimator of net survival was
made. A debate followed on the suitable methods to be
used [5–9].
While most of the work in the past focused on the
estimation of net survival, it is clear that being in a
competing risks setting, there are several other con-
cepts of interest. Estimation of crude mortality has
been proposed by Cronin and Feuer [10] and the
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usefulness of this measure has been studied by Eloranta
et al. [11].
With many methods available and several opposing
guidelines given in the literature [7–9, 12], a consider-
able confusion has arisen in the field, with the result that
many studies are not directly comparable since different
methodology was used for it. The differences between
the ideas underlying the different methods are subtle, so
in order to properly understand what should be used
and thus resolve the confusion of the field, we believe
that, before focusing on any methods, we should first
make a clear distinction between the measures and de-
scribe their interpretation. This is the main goal of our
paper.
The paper is organized as follows: the Methods section
reviews four measures of interest and states non-
parametric methods that consistently estimate them.
The Results section uses colon and prostate cancer data
and simulated data to illustrate the differences in inter-
pretation between the measures. The Discussion section
comments on the results and often used alternative
methods.
Methods
Measures of survival and mortality
It is crucial, when planning to analyze the survival ex-
perience of cancer patients, to decide upon the goal of
the analysis, i.e. which measure of population character-
istic we would like to evaluate with our data. We present
here four measures most frequently reported in the
literature.
 Overall survival (SO(t)) is the probability that a
patient is still alive at a certain time point t after the
diagnosis. It is directly related to the overall hazard
rate of dying λO – knowing one quantity implies
knowing the other. The mathematical relationship
between the two is formalized in the following
equation:
SO tð Þ ¼ exp −
Z t
0
λO uð Þdu
0
@
1
A ð1Þ
 Relative survival ratio (SR(t)) compares the overall
survival of the patients to the survival of the cancer-
free group with the same demographic structure by
calculating the ratio
SR tð Þ ¼ SO tð ÞSP tð Þ ð2Þ
The ratio describes how the observed survival of the
patients compares to the survival of a cancer-free
group with the same demographic structure.
While overall survival and relative survival ratio do
not distinguish between causes of death, the next two
concepts assume that the overall hazard λO can be split
into two additive components - that due to cancer (λC,
often referred to as cause-specific or excess hazard) and
that due to other causes (λP, often referred to as popula-
tion hazard):
λOi tð Þ ¼ λPi tð Þ þ λCi tð Þ ð3Þ
Recognizing that individuals may have different haz-
ards, we use the indicator i in the above equation.
 Cancer-related crude mortality (FC(t)) provides
additional information to overall mortality
(1 – overall survival). It not only reports the
probability of dying up to time t, but further
splits it into the probability of dying (up to t) from
cancer FC(t) and the probability of dying (up to t)
from other causes FP(t):
1−SO tð Þ ¼ FC tð Þ þ FP tð Þ
The term FC(t) is often referred to as the cancer
mortality in the presence of competing risks,
cumulative cause-specific mortality (Cronin and
Feuer [8]) or simply cancer-related crude mortality.
It can be expressed as
FC tð Þ ¼
Z t
0
SO u−ð ÞλC uð Þdu
The above formula simply says that in order for a
patient to die from cancer at time u, they must have
survived both causes until just before that time
(SO(u−)) and then succumb to hazard λC. Crude
mortality is a cumulative measure –it accumulates
deaths at any time u up to t, hence the integral.
Since the overall survival S0 depends on both
hazards, the same is true for the crude mortality.
 Net survival (SN(t)) should be considered if the
hazard attributed to cancer is the only hazard of
interest, therefore λO in equation (1) gets replaced
by λC:
SN tð Þ ¼ exp −
Z t
0
λC uð Þdu
0
@
1
A
Net survival is the only measure that does not
depend on the hazard due to other causes and this
is the measure to be used when the cancer survival
experience of groups with different population
mortality is to be compared.
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Crude mortality shall always be lower than net
mortality (1 − SN): some patients die from other
causes before dying from cancer.
Using formula (3), net survival of each individual
can be written as the ratio of the overall survival
probability of this patient and the survival
probability of his counterparts in the population.
Net survival of a group of size n can thus also be
interpreted as the average ratio of overall and
population survival:
SN tð Þ ¼ 1n
Xn
i¼1
SOi tð Þ
SPi tð Þ
On the other hand, the relative survival ratio (2)
of the same group can be written as the ratio of
averages:
SR tð Þ ¼
1
n
Xn
i¼1SOi tð Þ
1
n
Xn
i¼1SPi tð Þ
Obviously the two measures are not mathematically
equal and often differ substantially in practice,
the extent of the difference depends on the
heterogeneity of the individuals with respect to
the demographic variables and on the heterogeneity
of the individual cancer specific hazards.
Data settings
Two main settings can be defined according to the avail-
ability of the cause of death in the analyzed data. When
a cause of death is attributed to each patient, we shall
refer to cause-specific data setting. If the cause is not
known or unreliable (‘relative survival setting’), indirect
information on it can be obtained by merging our data
with the general population mortality data available from
national statistics, which present the mortality rate (λPi)
that the patients would experience if they had no cancer
(it can be shown that mortality from a specific cancer
forms a negligible part of the whole population mortal-
ity). Any excess to this mortality can thus be attributed
to cancer. Under this setting, relative survival methods,
the sole focus of this paper, are applied. Note that the
data setting affects the choice of the method of estima-
tion, but not the measure to be estimated.
Material
To illustrate the properties and interpretation of the
measures, we use both real and simulated data. We
first analyse data collected by the national population-
based cancer registry of Slovenia for patients diagnosed
at age 50 to 80 with colon (male and female subjects,
N = 3184) or prostate (N = 2586) cancer between 1990
and 2000, and followed up until the end of 2010 [13].
Time to event or censoring, but not the cause of death,
is known for each individual.
We then make a step further from other epidemio-
logical papers (e.g. [6, 12]) by analyzing simulated data,
where the truth is known and comparisons thus made
easier. We mimic real data to create two data sets A and
B with same demographic distributions, and assume that
(i) the cohorts were diagnosed in two different calendar
years (1990 and 2000) and thus had a different general
population mortality rate λPi; but (ii) the true, underlying
cancer prognosis did not improve between periods A
and B, i.e. the cancer-specific hazards λCi are the same.
The data sets are large (20000 patients each) to enable
clear distinction between the random variation and true
differences.
Since our examples are here to highlight the fact that
the measures are not equal, we have chosen the simu-
lation parameters so that these differences are rather
obvious – the cancer specific hazard in our sample is
not homogeneous, but depends rather strongly on age
(excess hazard ratio for age equals 1.1), the age of the
patients is asymetrically distributed between 50 and 80
with the older patients being more common in the
sample.
The information on the hazard of dying from other
causes is obtained from the official Slovene life tables
split by sex, age and calendar year.
Statistical methods
Overall survival is estimated using the Kaplan-Meier
method - all deaths are considered as events and no in-
formation on cause of death or population mortality is
needed.
Cronin and Feuer [10] described the methodology for
crude mortality estimation using data grouped by fixed-
length intervals of follow-up time, we use the continu-
ous time version here.
Net survival is estimated using the recently introduced
estimator by Pohar Perme et al. [4] (PP estimator).
Relative survival ratio is estimated using the Ederer I
method [1].
Results
We first consider the cohort of colon cancer patients.
Ten-year overall survival equals 0.29 (Fig. 1a). The cor-
responding 10-year overall mortality of 0.71 (1–0.29)
can be split into the probability that a patient dies from
colon cancer (0.55) and the probability that a patient
dies from other causes (0.16) (Fig. 1b).
Ten-year net survival equals 0.44 (Fig. 1c), i.e. if the
patients could only die of cancer, 56% of them would die
in the first 10 years after the diagnosis of cancer. This
number is slightly higher than the crude probability of
dying from the cancer since some patients, in particular
Pohar Perme et al. BMC Cancer  (2016) 16:933 Page 3 of 8
older patients, died from other causes before they could
die of cancer. Finally, the 10-year relative survival ratio
(Fig. 1d) is estimated at 0.44, implying that after 10 years,
the survival of our observed cohort is at 44% of the sur-
vival of their population counterparts. In this example
net and relative survival ratio estimates are equal, but as
shown next, this does not have to be the case.
Since the cancer patients do not die of cancer only,
net survival may seem the least interesting measure.
However, its importance becomes obvious when we wish
to compare two groups of patients. In our simulated
data, the overall survival shows improvement: 10-year
survival of the more recently diagnosed cohort B (blue)
was 0.52 compared to 0.50 for the earlier cohort A
(black, Fig. 2a). The data was simulated so that this im-
provement in survival is entirely due to improvement in
the general population mortality, and this is correctly
shown by the equal estimates of net survival in periods
A and B (Fig. 2c). By contrast, this information is not
obvious from Fig. 2b and d. As expected, the probability
of dying from other causes decreased, the decrease after
10 years of follow-up is by 0.03 compared to patients A.
However, some of them died from cancer in this period,
hence the 0.01 increase in the probability of dying from
cancer. Similarly, since the cancer treatment did not
improve, but the population survival did, the relative
survival ratio of cohort B is lower than that of cohort A
(Fig. 2d). In summary, while net survival correctly de-
scribes potential change in cancer hazard, neither the
crude cancer mortality nor the relative survival ratio can
disentangle changes in both components.
We now turn to comparing the colon and prostate
cancer mortality at 5 and 10 years with respect to age
(Fig. 3).
Among colon cancer patients, the overall mortality
(stars) increases with age. After 10 years, overall mortal-
ity rises from 0.61 for the 50–55 years group to 0.87 for
the 75–80 group. The same is true for their probability
Fig. 1 The four measures. Colon cancer survival (1990–2000 patients, Slovenia cancer registry): a) Overall survival, b) Crude mortality, c) Net
survival, d) Relative survival ratio. Dashed lines denote the 95% confidence intervals. Parts a), b) and c) present probabilities, part d) is a ratio
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of dying from other causes (empty circles), which is
around 25% higher in the oldest group compared to the
youngest. On the contrary, their probability of dying
from cancer (filled circles) does not change much with
age group – after 10 years, 57% of colon cancer patients
are estimated to have died from their cancer – and this
is also true for net mortality.
By contrast, among prostate cancer patients, the over-
all mortality is lower in 55–65 than at age 50–55, then
increases with age. Net mortality shows a fairly compar-
able age-related pattern. The probability of dying from
the cancer decreases steadily until age 65–70 where it
plateaus at 0.43, close to the probability of dying from
other causes reached by the oldest age group.
The relative survival ratio is practically the same as net
survival in all four graphs and thus not included in the
graphs to avoid visual clutter.
Discussion
Our examples illustrate how the described measures
provide fundamentally different, but complementary,
information.
This is best illustrated by the 10-year age-related pat-
terns for prostate cancer (Fig. 3d). The U-shape curve of
net mortality reflects the worse prognosis of prostate
cancer among young and old patients. However, among
young patients, net mortality and probability of dying
from the cancer are very comparable because these pa-
tients mostly died from their cancer, as shown by their
very low probability of dying from other causes. By con-
trast, despite high net mortality denoting a poor progno-
sis of prostate cancer, less than half of old patients died
from their cancer. However, because of the rapid, secular
increase in life expectancy, i.e. decrease in probability of
dying from other causes, the gap between net and crude
Fig. 2 Comparing two cohorts with the different measures. Colon cancer survival (simulated data): a) Overall survival, b) Crude mortality, c) Net
survival, d) Relative survival ratio. Black curves: cohort A, diagnosed 1990; blue curves: cohort B, diagnosed 2000. Dashed lines denote the 95%
confidence intervals for cohort A
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cancer mortalities implies that prostate cancer may be-
come an even bigger public health problem in a near
future. Indeed, the number of deaths due to prostate
cancer may increase dramatically among the elderly pa-
tients if net survival of prostate cancer, i.e. its prognosis,
does not improve significantly.
The choice of which measure to report is delicate.
Crude mortality is more relevant for health policy-
makers [11, 14], since it quantifies the actual contribu-
tion of the disease to overall mortality. Net survival is
the survival probability derived solely from the cancer-
specific hazard of dying. Because it is unaffected by
differences in mortality from other causes, it is the
only measure allowing a proper comparison of differ-
ent populations according to time, geography or other
characteristics.
However, this does not mean that an observed differ-
ence in net survival between two groups cannot come
from their different demographic structure – for ex-
ample, if age affects the cancer specific hazard, then the
net survival of groups with different age structure is
expected to differ and has to be taken into account for
example by age-standardization.
Relative survival ratio used to be the main reported
measure as it was thought to equal net survival. We
believe it may be still appealing as a direct comparison
between the overall survival of the patients and the ex-
pected survival from the general population.
Two further terms, “relative survival” and “cause-specific
survival”, are still often used in the literature as they would
describe measures. The former is confusing as it could
apply to any measure within the “relative survival setting”.
The latter is unfortunate since, while cause-specific mor-
tality aims to estimate the proportion of patients dying
from each specific cause, one has to survive all causes to
be still alive. We propose to avoid both terms.
Once the measure of interest is determined, one
should choose among the methods that estimate it. We
describe here the most common alternatives that appear
in the field.
Fig. 3 Colon and prostate cancer mortality with respect to age. Colon (upper row) and prostate (lower row) cancer mortality after 5 (left) and 10
(right) years (1990–2000 patients, Slovenia cancer registry)
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One option is to use model-based predictions, i.e. a
parametric estimator of the measures. Here, one should
keep in mind that the first step in the analysis of survival
data is the non-parametric estimation of the survival
curve, which gives us a description of the data. This ana-
lysis may be followed by modelling the effect of covari-
ates (looking at trends, etc.), which requires modelling
assumptions, that can be rather complex and often in-
clude interactions. In any case the model specification
needs to be checked; a first evaluation can be done sim-
ply by drawing the survival curve predicted by the model
and check whether it fits well to the non-parametric
curve. Therefore, as for any type of analysis, using only
the parametric approach to describe the data is not ap-
propriate, but once the model is in this way proven to
be acceptable, it is a powerful tool to understand the
data in depth and make predictions.
A lot of confusion exists about the non-parametric
method to use for net survival estimation while the esti-
mation proposals of the above three other measures are
quite clear. In the past, the Ederer I or its correction, the
Hakulinen method, has been used for estimation. More
recently, some authors claim Ederer II should be used
[12], but all three methods have been theoretically
proven not to be consistent [4]. While the bias in small
samples might be hard to discern due to large variation,
it still persists in large samples (i.e. the method is not
consistent), where variation of the estimates becomes
negligible. An example is given in our simulated data
set, where at 10 years Ederer II misses the true value by
5% (Fig. 4) and Ederer I misses it for 13% (Fig. 2). This
means that, though analysing these same data, one
would conclude to significantly different results. Further-
more, a researcher using the Ederer II method on our
data would wrongfully conclude that net survival wors-
ened from 1990 to 2000. This example illustrates how
the choice of approach can affect results of comparisons
between population groups, an issue already raised by
Seppå et al. [6].
Fortunately, most publications in the past reported
“age-standardized results”, which implies analysis strati-
fied by age and sex, a situation in which the Ederer I,
Hakulinen and Ederer II methods give comparable re-
sults, provided that the stratification was fine enough. In
that case, all patients of each strata have roughly the
same hazard and therefore, the relative survival ratio
and net survival within the strata become roughly equal.
Recent publications have focused on age-stratified
Ederer II [8, 9] and have used simulations to support
this theoretical fact and to evaluate the size of the bias
in practice where the age intervals for stratification are
rather wide. Further, the mean square errors of the age-
stratified Ederer II were compared to those of the PP
method, but the simulations were largely affected by the
fact that they included very old patients, for whom very
little or no information on long-term net survival is
Fig. 4 Ederer II and PP estimator. The comparison of Ederer II (blue solid curve) and PP estimator (black solid curve) on the simulated data set A.
The dashed curves present the confidence intervals for each method
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available in the data since their probability of dying of
other causes is so high. In such cases, the variance of the
PP method becomes very large reflecting that no infor-
mation is available to estimate net survival of the old
patients. On the other hand the variance of the age-
stratified Ederer II remains comparatively small, since
the estimator relies on the assumption that the younger
patients still in the risk set carry the required information.
In practice, this assumption may or may not be true,
therefore, their variance and bias strongly depended on
the simulation parameters and results presented in both
papers do not entirely agree. Further work may be needed
to clarify these issues.
In practice, a common criterion in choosing a certain
method is also the availability of the software. In the
relative survival setting, the most recently introduced
method is the PP estimator and the inexistence of this
method in some of the standard software (e.g. SAS) can
be a clear reason for the age-stratified Ederer II method
to be used. However, the command availability is not a
problem for the R or Stata users. All the methods men-
tioned in this paper are available in R package relsurv
[15], in Stata, the commands stns [16], strs [17] and
stnet [18] include the required options. In SEER*Stat the
PP estimator is under development.
Conclusion
In conclusion, we have shown that to provide proper
information for cancer control policy all four measures
- the overall survival, the relative survival ratio, the
crude mortality and the net survival are useful. After
determining the measure, we should then choose the
method that estimates that measure consistently. When
estimating net survival, the traditional methods (Ederer I,
Hakulinen, Ederer II) could only be used as a reasonable
approximation if they are properly stratified. On the other
hand, Ederer I is a perfectly valid estimator of relative
survival ratio and, as such, even within heterogeneous
population.
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